EXPRESSION OF PXR, MDR1, CYP3A5, AND CYP2B6 IN HIGH-GRADE SEROUS OVARIAN CANCER AND ITS SIGNIFICANCE

• Published in: 精准医学杂志 Vol. 38; no. 2; pp. 135 - 139
• Main Author: ZHANG Ping, MA Lan, CHEN Hua
• Format: Journal Article
• Language: Chinese
• Published: Editorial Office of Journal of Precision Medicine 01.04.2023
• Subjects: high grade serous ovarian cancer|pxr|mdr1|cyp3a5|cyp2b6|mdr|chemotherapy resistant
• ISSN: 2096-529X
• DOI: 10.13362/j.jpmed.202302009

Objective To investigate the expression and significance of progesterone X receptor (PXR), multidrug resistant protein 1 (MDR1), cytochrome P450 3A5 (CYP3A5), and cytochrome P450 2B6 (CYP2B6) in high-grade serous ovarian cancer (HGSOC). Methods A total of 56 patients with HGSOC admitted to the Department of Gynecology, Qingdao Municipal Hospital from September 2019 to December 2021 were included in the experimental group. The patients were further divided into drug resistant group (24 cases) and sensitive group (32 cases) according to their resistance to platinum chemotherapy drugs. The control group included 16 patients with uterine fibroids admitted during the same period. The expression of PXR, MDR1, CYP3A5, and CYP2B6 in HGSOC and normal fallopian tubes were determined by immunohistochemistry, real-time quantitative PCR, and Western blotting. Results Compared with the control group, the positive expression rates of PXR, MDR1, CYP3A5, and CYP2B6 were significantly increased in the experimental group (χ2=12